| Acquired Immunodeficiency Syndrome |
NCT00131560: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV |
|
|
| Active, not recruiting | 2 | 60 | US | VRX496-Modified Autologous T cells | VIRxSYS Corporation | HIV Infection | 11/08 | 06/23 | | |
| Active, not recruiting | 2 | 40 | US | VRX496-transduced autologous CD4 T cells | VIRxSYS Corporation | HIV Infections | 01/09 | 06/23 | | |
NCT00046345: Atazanavir for HIV Infected Individuals: An Early Access Program |
|
|
| No Longer Available | N/A | | US | Atazanavir (BMS-232632) | Bristol-Myers Squibb | HIV Infections | | 07/03 | | |
NCT00162227: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection |
|
|
| No Longer Available | N/A | | US | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
NCT00162188: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada |
|
|
| No Longer Available | N/A | | Canada | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
NCT00801515: A Compassionate Access Protocol For Those Patients Who Have Completed A4001029 |
|
|
| No Longer Available | N/A | | Canada | Maraviroc, Celsentri | ViiV Healthcare, Pfizer | HIV | 07/11 | 07/11 | | |
NCT01776996: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc |
|
|
| No Longer Available | N/A | | Europe, RoW | Continued Access Arm | ViiV Healthcare, GlaxoSmithKline | Infection, Human Immunodeficiency Virus | | | | |
CD02_EA, NCT02759042: An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study |
|
|
| No Longer Available | N/A | | US | PRO 140, PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5 | CytoDyn, Inc., Amarex Clinical Research | HIV | | | | |
NCT00992654: A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India |
|
|
| No Longer Available | N/A | | NA | Open Label Treatment Access: Maraviroc, Maraviroc, Celsentri, Selzentry | ViiV Healthcare, Pfizer | Human Immunodeficiency Virus (HIV) | | | | |
NCT03010332: Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease |
|
|
| No Longer Available | N/A | | NA | Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs), ATA230 | Atara Biotherapeutics | CMV Viremia, CMV Disease | | | | |